MITF and melanoma: Another sensational discovery of SUMO‐kidney was recently made in melanoma and renal cell carcinoma (RCC).106 The microphthalmia‐associated transcription factor (MITF) has been proposed to act as a melanoma oncogene107; it also stimulates transcription of hypoxia inducible factor (HIF1),108 a pathway targeted by kidney cancer susceptibility genes.109 It was shown that the germline missense substitution in MITF (Mi‐E318K) had a greater than five‐fold increased risk of developing melanoma, RCC or both cancers.